10-Q: Personalis Inc. Reports Q3 2024 Results: Revenue Surges 41% Driven by Pharma Growth

Personalis Inc. saw a 41% increase in revenue in Q3 2024, primarily driven by a 96% surge in pharma test revenue, while also securing significant financing.

Summary

• Personalis Inc. reported a 41% increase in total revenue for the third quarter of 2024, reaching $25.7 million, compared to $18.2 million in the same period of 2023.
• The growth was primarily fueled by a 96% increase in revenue from pharma tests and services, which rose to $15.7 million.
• Enterprise sales, however, decreased by 33% to $5.3 million, and population sequencing revenue increased by 85% to $4.4 million.
• The company delivered 945 molecular tests in Q3 2024, a 68% increase compared to the previous quarter.
• Personalis raised approximately $35 million in net financing from Tempus AI, Inc., and an additional $27.2 million from its At-The-Market (ATM) program.
• The company's net loss for the quarter was $39.1 million, or $0.64 per share, compared to a net loss of $29.1 million, or $0.60 per share, in Q3 2023.
• For the nine months ended September 30, 2024, total revenue was $67.8 million, a 26% increase compared to $53.8 million in the same period of 2023.
• The net loss for the nine-month period was $64.9 million, or $1.19 per share, compared to a net loss of $81.7 million, or $1.71 per share, in the same period of 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth is strong and the company has secured significant financing, the increasing net loss and reliance on a few key customers are concerning. The company's strategic partnerships and focus on key indications are positive, but the overall sentiment is cautiously optimistic.

Positives

• The company experienced a significant increase in revenue, driven by strong growth in pharma tests and services.
• The company successfully raised substantial capital through strategic financing and its ATM program.
• The number of molecular tests delivered increased significantly, indicating growing demand for the company's services.
• Positive clinical data for NeXT Personal was presented at a major medical conference.
• The company secured a new task order from the VA MVP, ensuring continued revenue from this source.

Negatives

• The company's net loss increased in Q3 2024 compared to the same period in 2023.
• Enterprise sales revenue decreased by 33% in Q3 2024.
• The company expects revenue from one of its personalized cancer therapy customers to decline over the next few quarters.
• The company expects its commercial relationship with Natera to wind down by the end of 2024.

Risks

• The company has a history of losses and expects to incur significant losses for the foreseeable future.
• The company relies on a limited number of customers for a substantial portion of its revenue.
• The company is subject to risks associated with the development and commercialization of new services and products.
• The company is subject to risks associated with regulatory compliance and intellectual property protection.
• The company is subject to risks associated with cybersecurity and data privacy.
• The company is subject to risks associated with the volatility of the market price of its common stock.
• The company is subject to risks associated with the potential for future sales of shares by existing stockholders.
• The company is subject to risks associated with the potential for future dilution of its common stock.
• The company is subject to risks associated with the potential for future changes in tax laws or regulations.
• The company is subject to risks associated with the potential for future changes in health care policy.
• The company is subject to risks associated with the potential for future disruptions to its supply chain.
• The company is subject to risks associated with the potential for future disruptions to its facilities.
• The company is subject to risks associated with the potential for future disruptions to its information technology systems.
• The company is subject to risks associated with the potential for future litigation.
• The company is subject to risks associated with the potential for future changes in accounting standards.
• The company is subject to risks associated with the potential for future changes in economic conditions.
• The company is subject to risks associated with the potential for future changes in geopolitical conditions.
• The company is subject to risks associated with the potential for future health crises.
• The company is subject to risks associated with the potential for future changes in environmental, social and corporate governance (ESG) matters or its reporting of such matters.

Future Outlook

The company anticipates fulfilling the new task order received in September 2024 during the first three quarters of 2025. The company expects revenue from one of its personalized cancer therapy customers to decline over the next few quarters. The company expects its commercial relationship with Natera to wind down by the end of 2024.

Management Comments

• The company is working with a growing number of leading cancer centers and world-class academic research institutions to build and publish the clinical evidence-base to support our products and our key indications, as well as to obtain reimbursement coverage from Medicare and other payors.
• If the key opinion leaders (KOLs) we are collaborating with have a positive experience using our products, we are optimistic this will support broader use of our products by other KOLs, as well as clinicians in the future.
• We believe that our capacity is already larger than most cancer genomics companies, and we continue to build automation and other infrastructure to scale further as demand increases.

Industry Context

The company operates in the competitive cancer genomics market, facing competition from both established and emerging companies. The company's focus on personalized cancer therapies and its partnerships with pharmaceutical companies and diagnostic companies align with current industry trends. The company's expansion into the clinical diagnostics market and its collaboration with Tempus AI, Inc. are also indicative of the industry's move towards more personalized and accessible testing options.

Comparison to Industry Standards

• Personalis's revenue growth of 41% in Q3 2024 is strong compared to some of its peers in the genomics and diagnostics space, though direct comparisons are difficult due to varying business models and reporting segments.
• Companies like Guardant Health and Exact Sciences, which also focus on cancer diagnostics, have reported varying growth rates, with some experiencing slower growth due to market conditions and competition.
• Personalis's focus on pharma partnerships and clinical trial support is a common strategy in the industry, with companies like Caris Life Sciences and Foundation Medicine also pursuing similar avenues.
• The company's investment in automation and infrastructure to scale its operations is consistent with the industry's need to handle increasing volumes of genomic data.
• The company's collaboration with Tempus AI, Inc. is similar to other partnerships in the industry aimed at expanding market reach and commercialization efforts.
• The company's net loss, while significant, is not uncommon for companies in the growth phase of the genomics and diagnostics industry, as they often prioritize investments in research and development and commercialization over immediate profitability.
• The company's reliance on a few key customers is a common risk in the industry, as many companies depend on large pharmaceutical and diagnostic partners for a significant portion of their revenue.

Legal Proceedings

• In June 2024, the Company and Foresight Diagnostics Inc. entered into a Settlement and License Agreement to settle litigation related to alleged patent infringement by Foresight.

Related Party Transactions

• The company has a Commercialization and Reference Laboratory Agreement with Tempus AI, Inc., under which Tempus markets the company's NeXT Personal Dx test in the United States.
• The company issued warrants to Tempus AI, Inc., which were exercised in full in August 2024.
• The company entered into an investment agreement with Tempus AI, Inc., in August 2024, under which the company issued and sold 3,500,000 shares of common stock at a price per share of $5.07.

Stakeholder Impact

• Shareholders may be concerned about the increasing net loss, but encouraged by the strong revenue growth and strategic partnerships.
• Employees may be affected by the company's restructuring activities and workforce reductions.
• Customers may benefit from the company's expanded testing capabilities and clinical evidence.
• Suppliers may be affected by the company's reliance on a limited number of suppliers and potential supply chain disruptions.
• Creditors may be affected by the company's debt obligations and financial performance.

Next Steps

• The company plans to fulfill the new task order received from the VA MVP during the first three quarters of 2025.
• The company will continue to focus on scaling its infrastructure and expanding its commercial reach.
• The company will continue to develop and publish clinical evidence to support its products and key indications.
• The company will continue to seek reimbursement coverage from Medicare and other payors.

Key Dates

Keywords

genomic testing, cancer diagnostics, precision oncology, personalized medicine, molecular tests, liquid biopsy, pharmaceutical partnerships, clinical trials, sequencing services, data analysis, Medicare reimbursement, Tempus AI, VA MVP, Natera, Moderna